A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules and Placebo in Schizophrenia and Schizophrenia; Psychosis, sponsored by Karuna Therapeutics. Completed at 32 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by Karuna Therapeutics (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.
Among the 20 studies testing xanomeline in Schizophrenia, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 4th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Argentina, Bulgaria and 4 more countries
Ages 18–65
New York State Psychiatric Institute · Sites in United States
Ages 18–50
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Australia, Canada and 8 more countries
Ages 5–17
Bristol-Myers Squibb · Sites in United States, Colombia, Japan and 1 more country
Ages 13–17
Bristol-Myers Squibb · Sites in United States
Ages 18–65
By country, each count listing its studies:
xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 14 · Phase 4 3
First in 2018; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 20 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 7 most frequent:
This study is registered under Karuna Therapeutics, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Karuna Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
21 studies in Schizophrenia by Bristol-Myers Squibb: 8 open now, 9 under way, 4 of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 21 studies in Schizophrenia by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2021, is one of 13 in phase 3, and was the 5th registered.
Bristol-Myers Squibb’s Schizophrenia studies by the year they started, since 2016.
2 of the studies testing xanomeline in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07423546New York State Psychiatric InstituteA PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia | 2027-04-30 |
| NCT07061288Bristol-Myers SquibbA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing xanomeline in Schizophrenia, from their registry updates:
Among Bristol-Myers Squibb’s 21 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores in adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate improvement in disease severity and symptoms, safety and tolerability, and pharmacokinetics in adult inpatients with a DSM-5 diagnosis of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is capable of providing .
Subject is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening.
Positive and Negative Syndrome Scale total score between 80 and 120, inclusive. Score of ≥4 (moderate or greater) for ≥2 of the following Positive Scale (P) items:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo
Drug pages: Xanomeline · Trospium chloride
Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
Placebo Capsules
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of participants with schizophrenia and is widely used in the study of antipsychotic therapy. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility, and the negative symptoms in schizophrenia are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as the PANSS score at screening.
Time frame: From baseline up to Week 5
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5
PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility. If a patient has a PANSS assessment recorded and no more than 2 items are missing from the PANSS positive scales, then the PANSS Positive Score will be calculated as the average of the non-missing items multiplied by 7. If 3 or more items are missing (\> 30%) at a particular visit, the respective positive score at the visit will not be calculated and will be treated as missing data. Baseline is defined as the PANSS score at screening.
Time frame: From baseline up to Week 5
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5
PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions. If a participant has a PANSS assessment recorded, and no more than 2 items are missing from the PANSS negative scales, then the PANSS Negative Score will be calculated as the average of the non-missing items multiplied by 7. If 3 or more items are missing (\> 30%) at a particular visit, the respective negative score at the visit will not be calculated and will be treated as missing data. Baseline is defined as the PANSS score at screening.
Time frame: From baseline up to Week 5
Positive and Negative Syndrome Scale (PANSS) Negative Marder Factor Score Change From Baseline at Week 5
PANSS Marder factor score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Baseline is defined as the PANSS score at screening.
Time frame: From baseline up to Week 5
Clinical Global Impression-Severity (CGI-S) Score Change From Baseline at Week 5
Clinical Global Impression-Severity (CGI-S) Score is a measurement to evaluate severity and treatment response in schizophrenia. Completed independently by a clinician, the CGI-S assesses extremely ill patients, by asking 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness. The CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients. This scale reflects the total score. Baseline is defined as CGI-S score at screening. The change from baseline in total score is reported.
Time frame: From baseline up to Week 5
Number of Participants Who Achieve >=30% Reduction in Positive and Negative Symptoms Scale (PANSS) Total Score From Baseline to Week 5
Positive and Negative Syndrome Scale (PANSS) is a scale used for measuring symptom severity of subjects with schizophrenia and is widely used in the study of antipsychotic therapy. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Subjects are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility, and the negative symptoms in schizophrenia are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as screening. Note: Floor adjusted data were used for this analysis. Floor adjusted total score = total score - 30.
Time frame: From baseline up to Week 5
Number of Participants Experiencing Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose up to Day 42
Number of Participants Experiencing Cholinergic Symptom Adverse Event
The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.
Time frame: From first dose up to Day 42
Change From Baseline in Simpson-Angus Scale Total Score (SAS)
The Simpson-Angus Scale (SAS) is an established instrument to measure drug-related extrapyramidal syndromes. It is a 10-item testing instrument used to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. The range of scores is from 0 to 40 with increased scores indicating increased severity. Baseline is defined as the Simpson-Angus Scale score recorded on Day -1.
Time frame: From baseline up to week 5
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Total Score
The BARS for akathisia is a rating scale used to assess the severity of drug-induced akathisia, or restlessness, involuntary movements and inability to sit still. The range of scores is 0 to 14, with higher scores indicating greater severity. Baseline is defined as the BARS score recorded on Day -1.
Time frame: From baseline up to week 5
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
The AIMS is a rating scale that is used to measure involuntary movements known as tardive dyskinesia, which can sometimes develop as a side effect of long-term treatment with antipsychotic medications. This measurement was a 12-item scale to assess orofacial, extremity, and truncal movements as well as the overall severity, incapacitation, and the participant's level of awareness of the movements. Items are scored from 0 (none) to 4 (severe). A higher score indicates more severe dyskinesia. Baseline is defined as the AIMS score recorded on Day -1. The total score is the sum of sub scores for items 1-7. The first 7 items are used to measure the severity of abnormal movements in the orofacial region (4 items: facial muscles, lips, jaw, tongue), upper extremities (1 item), lower extremities (1 item), and trunk (1 item). Change from baseline for the total scores are reported.
Time frame: From baseline up to week 5
Number of Participants Who Experienced Weight Change
The number of participants who lost weight, maintained their weight, or gained weight between baseline and week 5. Baseline is defined as measurements taken at screening.
Time frame: From baseline up to week 5
Change From Baseline in Body Mass Index (BMI)
The change in Body Mass Index (BMI) from baseline up to week 5. BMI is a person's weight in kilograms divided by the square of height in meters. Baseline is defined as measurements taken at screening.
Time frame: From baseline up to week 5
Change From Baseline in Waist Circumference
The change in waist circumference in centimeters from baseline up to week 5. Baseline is defined as measurements taken at screening.
Time frame: From baseline up to week 5
Change From Baseline in Orthostatic Vital Signs - Blood Pressure
The change from baseline in orthostatic diastolic and systolic blood pressure measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.
Time frame: From baseline up to week 5
Change From Baseline in Orthostatic Vital Signs - Heart Rate
The change from baseline in orthostatic heart rate measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.
Time frame: From baseline up to week 5
Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate
The change from baseline up to Day 35 or early termination in ECG mean heart rate. Baseline is defined as measurements taken at screening.
Time frame: From baseline up to Day 35 or early termination
Number of Participants Experiencing Clinically Significant Abnormal Physical Examination Results
The number of participants experiencing clinically significant abnormal physical examination results. Baseline is defined as measurements taken at screening.
Time frame: From baseline up to week 5
Number of Participants Experiencing Each Suicidal Ideation Scale Category as Per Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS assesses suicidal behavior and ideation on a scale with 4 general categories: suicidal ideation, intensity of ideation, suicidal behavior, and actual attempts. C-SSRS comprehensively identifies suicidal events while limiting the over identification of suicidal behavior. The C-SSRS was administered by a trained rater at the site. This study used 2 versions of the C-SSRS. At the Screening Visit, the "Lifetime" version was completed; for all subsequent visits, the "Since Last Visit" version of the C-SSRS was administered. Risk for suicidal behavior during the study was determined by the investigator's clinical assessment and C-SSRS as confirmed by the following: * Answering "Yes" on items 4 or 5 (C-SSRS - ideation) with the most recent episode occurring within the 2 months before screening, or * Answering "Yes" to any of the 5 items (C-SSRS behavior) with an episode occurring within the 12 months before screening. Non-suicidal, self-injurious behavior is not exclusionary.
Time frame: From screening up to Day 42
Area Under the Plasma Concentration-Time Curve (AUC)
AUC is the total area under the plasma drug concentration-time curve from time zero to 12 hours after drug administration. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.
Time frame: At days 8 and 28
Maximum Concentration (Cmax)
Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.
Time frame: At days 8 and 28
Time to Maximum Concentration (Tmax)
Tmax is defined as the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.
Time frame: At days 8 and 28
Mean Observed Hemoglobin Levels
The mean observed Hemoglobin levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 138 - 172 g/L Female: 121 - 151 g/L
Time frame: From baseline up to Days 21, 35, or early temination
Mean Observed Hematocrit Levels
The mean observed Hematocrit levels are displayed in percentages as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 40.7 - 50.3% Female: 36.1 - 44.3%
Time frame: From baseline up to Days 21, 35, or early temination
Mean Observed Erythrocyte Levels
The mean observed erythrocyte levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 4.7 - 6.1 10\^12 cells/L Female: 4.2 - 5.4 10\^12 cells/L
Time frame: From baseline up to Days 21, 35, or early temination
Mean Observed Platelets Levels
The mean observed platelet levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 150-450 10\^9 cells/L
Time frame: From baseline up to Days 21, 35, or early temination
Mean Observed Leukocytes Levels
The mean observed leukocytes levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 4.5-10 10\^9 cells/L
Time frame: From baseline up to Days 21, 35, or early temination
Mean Observed Lymphocytes Levels
The mean observed lymphocytes levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 1-4.8 10\^9 cells/L
Time frame: From baseline up to Days 21, 35, or early temination
Mean Observed Activated Partial Thromboplastin Time
The mean observed activated partial thromboplastin times in seconds are displayed as measured at the specified timepoints. Baseline is defined as first dose.
Time frame: From baseline up to Days 21, 35, or early temination
Mean Observed Prothrombin Time
The mean observed prothrombin times are displayed as measured at the specified timepoints. Baseline is defined as first dose.
Time frame: From baseline up to Days 21, 35, or early temination
Mean Observed Urinalysis - pH
The mean observed pH of participants' urine are displayed as measured at the specified timepoints. Baseline is defined as first dose. Urinalysis was completed using dipstick. Urinalysis was not completed if the local dipstick was normal.
Time frame: From baseline up to Days 21, 35, or early temination
Mean Observed Urinalysis - Prolactin
The mean observed prolactin levels of participants' urine are displayed as measured at the specified timepoints. Baseline is defined as first dose. Urinalysis was not completed if the local dipstick was normal.
Time frame: From baseline up to Days 21, 35, or early temination
The Number of Participants With Positive Drug Screen Results
A National Institute on Drug Abuse-5 urine drug screen (cannabinoids or marijuana, phencyclidine, amphetamines, opiates, and cocaine) was performed at screening and at baseline (Visit 2a \[Day -1\]). If a participant left the study site, they were to have a urine drug screen and test for alcohol (breathalyzer or urine alcohol level) upon returning to the study site.
Time frame: At screening, at Dat -1, and upon return from departure from study site at any time up to Day 42
The Number of Participants With Elevated Liver Function Test Results
The liver function test results (ALT, AST, ALP, total bilirubin, GGT) were specifically monitored to watch for any participants who met the FDA drug-induced liver injury (DILI) criteria. A summary of elevated liver function test results by visit is provided. Baseline is defined as measurements taken at screening. Monitoring for DILI criteria includes close observation initiated with ALT or AST \>3 × ULN; discontinuation of treatment should be considered if ALT or AST \>8 × ULN, ALT or AST \>5 × ULN for more than 2 weeks, ALT or AST \>3 × ULN and (total bilirubin \>2 × ULN or international normalized ratio \>1.5), or ALT or AST \>3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia (\>5%).
Time frame: From screening up to Day 42
| Milestone | KarXT | Placebo |
|---|---|---|
| Started | 125 | 131 |
| Recieved treatment | 125 | 128 |
| Completed | 79 | 93 |
| Not completed | 46 | 38 |
| Withdrew: Changes in condition making participant ineligible for further treatment | 1 | 0 |
| Withdrew: Progressive disease | 0 | 4 |
| Withdrew: Adverse event | 8 | 7 |
| Withdrew: Other reasons | 0 | 1 |
| Withdrew: Suicidal or assaultive behavior | 0 | 2 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Consent withdrawn | 35 | 22 |
The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of participants with schizophrenia and is widely used in the study of antipsychotic therapy. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility, and the negative symptoms in schizophrenia are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as the PANSS score at screening.
| Score on a scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 | -20.6 ± 1.584 | -12.2 ± 1.552 |
PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility. If a patient has a PANSS assessment recorded and no more than 2 items are missing from the PANSS positive scales, then the PANSS Positive Score will be calculated as the average of the non-missing items multiplied by 7. If 3 or more items are missing (\> 30%) at a particular visit, the respective positive score at the visit will not be calculated and will be treated as missing data. Baseline is defined as the PANSS score at screening.
| Score on a scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5 | -7.1 ± 0.499 | -3.6 ± 0.492 |
PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions. If a participant has a PANSS assessment recorded, and no more than 2 items are missing from the PANSS negative scales, then the PANSS Negative Score will be calculated as the average of the non-missing items multiplied by 7. If 3 or more items are missing (\> 30%) at a particular visit, the respective negative score at the visit will not be calculated and will be treated as missing data. Baseline is defined as the PANSS score at screening.
| Score on a scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5 | -2.7 ± 0.412 | -1.8 ± 0.405 |
PANSS Marder factor score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Baseline is defined as the PANSS score at screening.
| Score on a scale | KarXT | Placebo |
|---|---|---|
| Positive and Negative Syndrome Scale (PANSS) Negative Marder Factor Score Change From Baseline at Week 5 | -3.5 ± 0.484 | -2.7 ± 0.475 |
Clinical Global Impression-Severity (CGI-S) Score is a measurement to evaluate severity and treatment response in schizophrenia. Completed independently by a clinician, the CGI-S assesses extremely ill patients, by asking 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness. The CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients. This scale reflects the total score. Baseline is defined as CGI-S score at screening. The change from baseline in total score is reported.
| Score on a scale | KarXT | Placebo |
|---|---|---|
| Clinical Global Impression-Severity (CGI-S) Score Change From Baseline at Week 5 | -1.1 ± 0.091 | -0.6 ± 0.088 |
Positive and Negative Syndrome Scale (PANSS) is a scale used for measuring symptom severity of subjects with schizophrenia and is widely used in the study of antipsychotic therapy. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Subjects are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility, and the negative symptoms in schizophrenia are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as screening. Note: Floor adjusted data were used for this analysis. Floor adjusted total score = total score - 30.
| Participants | KarXT | Placebo |
|---|---|---|
| Number of Participants Who Achieve >=30% Reduction in Positive and Negative Symptoms Scale (PANSS) Total Score From Baseline to Week 5 | 40 | 23 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | KarXT | Placebo |
|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 88 | 64 |
The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.
| Participants | KarXT | Placebo |
|---|---|---|
| At Least One Procholinergic Symptom Adverse Event | 38 | 3 |
| At Least One Anticholinergic Symptom Adverse Event | 33 | 8 |
The Simpson-Angus Scale (SAS) is an established instrument to measure drug-related extrapyramidal syndromes. It is a 10-item testing instrument used to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. The range of scores is from 0 to 40 with increased scores indicating increased severity. Baseline is defined as the Simpson-Angus Scale score recorded on Day -1.
| Score on a Scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Simpson-Angus Scale Total Score (SAS) | -0.1 ± 0.56 | -0.1 ± 0.36 |
The BARS for akathisia is a rating scale used to assess the severity of drug-induced akathisia, or restlessness, involuntary movements and inability to sit still. The range of scores is 0 to 14, with higher scores indicating greater severity. Baseline is defined as the BARS score recorded on Day -1.
| Score on a Scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Barnes Akathisia Rating Scale (BARS) Total Score | -0.1 ± 0.75 | -0.1 ± 0.88 |
The AIMS is a rating scale that is used to measure involuntary movements known as tardive dyskinesia, which can sometimes develop as a side effect of long-term treatment with antipsychotic medications. This measurement was a 12-item scale to assess orofacial, extremity, and truncal movements as well as the overall severity, incapacitation, and the participant's level of awareness of the movements. Items are scored from 0 (none) to 4 (severe). A higher score indicates more severe dyskinesia. Baseline is defined as the AIMS score recorded on Day -1. The total score is the sum of sub scores for items 1-7. The first 7 items are used to measure the severity of abnormal movements in the orofacial region (4 items: facial muscles, lips, jaw, tongue), upper extremities (1 item), lower extremities (1 item), and trunk (1 item). Change from baseline for the total scores are reported.
| Units on a Scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score | 0.0 ± 0.45 | 0.0 ± 0.15 |
The number of participants who lost weight, maintained their weight, or gained weight between baseline and week 5. Baseline is defined as measurements taken at screening.
| Participants | KarXT | Placebo |
|---|---|---|
| Lost Weight | 1 | 0 |
| Maintained Weight1 | 72 | 80 |
| Gained Weight | 5 | 12 |
The change in Body Mass Index (BMI) from baseline up to week 5. BMI is a person's weight in kilograms divided by the square of height in meters. Baseline is defined as measurements taken at screening.
| kg/m^2 | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) | 0.457 ± 1.1340 | 0.666 ± 0.570 |
The change in waist circumference in centimeters from baseline up to week 5. Baseline is defined as measurements taken at screening.
| Centimeters | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Waist Circumference | 1.666 ± 4.8915 | 1.697 ± 4.8577 |
The change from baseline in orthostatic diastolic and systolic blood pressure measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.
| mmHg | KarXT | Placebo |
|---|---|---|
| Supine Systolic Blood Pressure | 1.9 ± 13.07 | 0.4 ± 13.00 |
| Supine Diastolic Blood Pressure | 2.2 ± 10.33 | 0.4 ± 9.30 |
| Standing Systolic Blood Pressure | 2.3 ± 14.07 | 0.1 ± 12.54 |
| Standing Diastolic Blood Pressure | 2.7 ± 9.93 | 0.1 ± 8.62 |
The change from baseline in orthostatic heart rate measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.
| beats/min | KarXT | Placebo |
|---|---|---|
| Supine Heart Rate | 11.9 ± 15.72 | 6.1 ± 14.02 |
| Standing Heart Rate | 9.86 ± 16.58 | 5.8 ± 13.85 |
The change from baseline up to Day 35 or early termination in ECG mean heart rate. Baseline is defined as measurements taken at screening.
| beats/min | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate | 11.5 ± 14.94 | 6.1 ± 14.62 |
The number of participants experiencing clinically significant abnormal physical examination results. Baseline is defined as measurements taken at screening.
| Participants | KarXT | Placebo |
|---|---|---|
| General Appearance - Baseline | 0 | 1 |
| General Appearance - Day 35 | 0 | 0 |
| Head, Eyes, Ears, Nose, Throat - Baseline | 0 | 0 |
| Head, Eyes, Ears, Nose, Throat - Day 35 | 0 | 0 |
| Thorax - Baseline | 0 | 0 |
| Thorax - Day 35 | 0 | 0 |
| Abdomen - Baseline | 1 | 0 |
| Abdomen - Day 35 | 0 | 0 |
| Cardiac - Baseline | 1 | 0 |
| Cardiac - Day 35 | 0 | 0 |
| Musculoskeletal - Baseline | 0 | 0 |
| Musculoskeletal - Day 35 | 0 | 0 |
| Circulatory System - Baseline | 0 | 0 |
| Circulatory System - Day 35 | 0 | 0 |
| Lymphadenopathy - Baseline | 0 | 0 |
| Lymphadenopathy - Day 35 | 0 | 0 |
| Limited Neurological Examination - Baseline | 1 | 0 |
| Limited Neurological Examination - Day 35 | 0 | 0 |
C-SSRS assesses suicidal behavior and ideation on a scale with 4 general categories: suicidal ideation, intensity of ideation, suicidal behavior, and actual attempts. C-SSRS comprehensively identifies suicidal events while limiting the over identification of suicidal behavior. The C-SSRS was administered by a trained rater at the site. This study used 2 versions of the C-SSRS. At the Screening Visit, the "Lifetime" version was completed; for all subsequent visits, the "Since Last Visit" version of the C-SSRS was administered. Risk for suicidal behavior during the study was determined by the investigator's clinical assessment and C-SSRS as confirmed by the following: * Answering "Yes" on items 4 or 5 (C-SSRS - ideation) with the most recent episode occurring within the 2 months before screening, or * Answering "Yes" to any of the 5 items (C-SSRS behavior) with an episode occurring within the 12 months before screening. Non-suicidal, self-injurious behavior is not exclusionary.
| Participants | KarXT | Placebo |
|---|---|---|
| Suicidal Ideation: Participant Wished to be Dead | 1 | 3 |
| Suicidal Ideation: Non-Specific Active Suicidal Thoughts | 1 | 1 |
| Suicidal Ideation: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act | 0 | 1 |
| Most Severe Ideation Level 1. Least Severe | 0 | 2 |
| Most Severe Ideation Level 2 | 1 | 0 |
| Most Severe Ideation Level 3 | 0 | 1 |
| Intensity of Ideation (Frequency) - Less than once a week | 0 | 1 |
| Intensity of Ideation (Frequency) - Once a week | 0 | 1 |
| Intensity of Ideation (Frequency) - 2-5 times a week | 1 | 1 |
| Intensity of Ideation (Duration) - Fleeting, a few seconds or minutes | 1 | 3 |
| Controllability - Easily able to control thoughts | 0 | 3 |
| Controllability - Can control thoughts with little difficulty | 1 | 0 |
| Deterrents - Does not apply | 0 | 1 |
| Deterrents - Deterrents definitely stopped participant from attempting suicide | 1 | 2 |
| Reasons for Ideation - Does not apply | 0 | 2 |
| Reasons for Ideation - Mostly to end or stop the pain | 0 | 1 |
| Reasons for Ideation - Completely to end or stop the pain | 1 | 0 |
AUC is the total area under the plasma drug concentration-time curve from time zero to 12 hours after drug administration. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.
| h*pg/mL | KarXT | Placebo |
|---|---|---|
| Trospium | 27800 ± 26000 | — |
| Xanomeline | 50200 ± 37900 | — |
Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.
| pg/mL | KarXT | Placebo |
|---|---|---|
| Trospium | 6070 ± 7780 | — |
| Xanomeline | 9660 ± 10500 | — |
Tmax is defined as the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug. Dose level 125/30 BID at Week 4 (Visit 8 \[Day 28\]) is reported.
| Hours | KarXT | Placebo |
|---|---|---|
| Trospium | 1.00 (0.00 to 3.95) | — |
| Xanomeline | 2.00 (0.00 to 12.00) | — |
The mean observed Hemoglobin levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 138 - 172 g/L Female: 121 - 151 g/L
| g/L | KarXT | Placebo |
|---|---|---|
| Baseline | 142.30 ± 18.098 | 142.71 ± 15.166 |
| Week 3 (Visit 7 [Day 21]) | 144.54 ± 19.096 | 146.27 ± 14.335 |
| Week 5 (Visit 10 [Day 35])/Early-Termination | 142.94 ± 19.175 | 144.40 ± 15.416 |
The mean observed Hematocrit levels are displayed in percentages as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 40.7 - 50.3% Female: 36.1 - 44.3%
| Percentage | KarXT | Placebo |
|---|---|---|
| Baseline | 44.52 ± 5.232 | 44.51 ± 4.553 |
| Week 3 (Visit 7 [Day 21]) | 45.12 ± 5.416 | 45.25 ± 4.306 |
| Week 5 (Visit 10 [Day 35])/Early-Termination | 44.51 ± 5.491 | 44.71 ± 4.595 |
The mean observed erythrocyte levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: Male: 4.7 - 6.1 10\^12 cells/L Female: 4.2 - 5.4 10\^12 cells/L
| 10^12 cells/L | KarXT | Placebo |
|---|---|---|
| Baseline | 5.025 ± 0.5072 | 4.894 ± 0.4498 |
| Week 3 (Visit 7 [Day 21]) | 5.130 ± 0.4986 | 5.165 ± 1.2161 |
| Week 5 (Visit 10 [Day 35])/Early-Termination | 5.058 ± 0.5339 | 5.003 ± 0.5139 |
The mean observed platelet levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 150-450 10\^9 cells/L
| 10^9 cells/L | KarXT | Placebo |
|---|---|---|
| Baseline | 334.04 ± 96.465 | 328.65 ± 92.288 |
| Week 3 (Visit 7 [Day 21]) | 334.47 ± 80.273 | 320.21 ± 73.757 |
| Week 5 (Visit 10 [Day 35])/Early-Termination | 336.59 ± 88.455 | 327.91 ± 75.834 |
The mean observed leukocytes levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 4.5-10 10\^9 cells/L
| 10^9 cells/L | KarXT | Placebo |
|---|---|---|
| Baseline | 5.971 ± 1.9465 | 6.384 ± 2.1421 |
| Week 3 (Visit 7 [Day 21]) | 6.046 ± 1.8090 | 6.252 ± 1.6685 |
| Week 5 (Visit 10 [Day 35])/Early-Termination | 6.199 ± 2.1814 | 6.184 ± 1.7208 |
The mean observed lymphocytes levels are displayed as measured at the specified timepoints. Baseline is defined as first dose. Reference Range: 1-4.8 10\^9 cells/L
| 10^9 cells/L | KarXT | Placebo |
|---|---|---|
| Baseline | 2.749 ± 0.9408 | 3.094 ± 3.9283 |
| Week 3 (Visit 7 [Day 21]) | 2.834 ± 0.9890 | 2.976 ± 0.9431 |
| Week 5 (Visit 10 [Day 35])/Early-Termination | 3.000 ± 1.2748 | 2.792 ± 0.8456 |
The mean observed activated partial thromboplastin times in seconds are displayed as measured at the specified timepoints. Baseline is defined as first dose.
| Seconds | KarXT | Placebo |
|---|---|---|
| Baseline | 30.75 ± 4.412 | 31.75 ± 5.897 |
| Week 3 (Visit 7 [Day 21]) | 32.43 ± 4.798 | 33.55 ± 7.858 |
| Week 5 (Visit 10 [Day 35])/Early-Termination | 31.48 ± 3.636 | 33.04 ± 6.775 |
The mean observed prothrombin times are displayed as measured at the specified timepoints. Baseline is defined as first dose.
| Seconds | KarXT | Placebo |
|---|---|---|
| Baseline | 1.00 ± 0.091 | 1.01 ± 0.086 |
| Week 3 (Visit 7 [Day 21]) | 1.02 ± 0.096 | 1.00 ± 0.086 |
| Week 5 (Visit 10 [Day 35])/Early-Termination | 1.01 ± 0.078 | 1.00 ± 0.083 |
The mean observed pH of participants' urine are displayed as measured at the specified timepoints. Baseline is defined as first dose. Urinalysis was completed using dipstick. Urinalysis was not completed if the local dipstick was normal.
| pH | KarXT | Placebo |
|---|---|---|
| Baseline | 5.52 ± 0.676 | 5.59 ± 0.800 |
| Week 3 (Visit 7 [Day 21]) | 5.33 ± 0.476 | 5.48 ± 0.748 |
| Week 5 (Visit 10 [Day 35]/Early Termination) | 5.48 ± 0.687 | 5.45 ± 0.621 |
The mean observed prolactin levels of participants' urine are displayed as measured at the specified timepoints. Baseline is defined as first dose. Urinalysis was not completed if the local dipstick was normal.
| ug/L | KarXT | Placebo |
|---|---|---|
| Baseline | 18.08 ± 21.767 | 17.38 ± 21.920 |
| Week 3 (Visit 7 [Day 21]) | 17.49 ± 19.422 | 14.50 ± 12.064 |
| Week 5 (Visit 10 [Day 35]/Early Termination) | 19.46 ± 24.668 | 15.56 ± 13.463 |
A National Institute on Drug Abuse-5 urine drug screen (cannabinoids or marijuana, phencyclidine, amphetamines, opiates, and cocaine) was performed at screening and at baseline (Visit 2a \[Day -1\]). If a participant left the study site, they were to have a urine drug screen and test for alcohol (breathalyzer or urine alcohol level) upon returning to the study site.
| Participants | KarXT | Placebo |
|---|---|---|
| The Number of Participants With Positive Drug Screen Results | 3 | 1 |
The liver function test results (ALT, AST, ALP, total bilirubin, GGT) were specifically monitored to watch for any participants who met the FDA drug-induced liver injury (DILI) criteria. A summary of elevated liver function test results by visit is provided. Baseline is defined as measurements taken at screening. Monitoring for DILI criteria includes close observation initiated with ALT or AST \>3 × ULN; discontinuation of treatment should be considered if ALT or AST \>8 × ULN, ALT or AST \>5 × ULN for more than 2 weeks, ALT or AST \>3 × ULN and (total bilirubin \>2 × ULN or international normalized ratio \>1.5), or ALT or AST \>3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia (\>5%).
| Participants | KarXT | Placebo |
|---|---|---|
| Baseline - Bilirubin (umol/L) > 1. 5 x ULN | 1 | 0 |
| Baseline - Gamma Glutamyl Transferase (U/L) > 2 x ULN | 4 | 4 |
| Baseline - Alanine Aminotransferase (U/L) > 3 x ULN | 0 | 0 |
| Baseline - Aspartate Aminotransferase (U/L) > 3 x ULN | 0 | 0 |
| Baseline - Alkaline Phosphatase (U/L) > 105 x ULN | 0 | 0 |
| Baseline - Hy's Law Cases | 0 | 0 |
| Visit 4 Day 7 - Gamma Glutamyl Transferase (U/L) > 2 x ULN | 0 | 1 |
| Visit 7 Day 21 - Alanine Aminotransferase (U/L) > 3 x ULN | 1 | 0 |
| Visit 7 Day 21 - Alanine Aminotransferase (U/L) > 5 x ULN | 2 | 0 |
| Visit 7 Day 21 - Aspartate Aminotransferase (U/L) > 3 x ULN | 1 | 0 |
| Visit 7 Day 21 - Alkaline Phosphatase (U/L) > 2 x ULN | 1 | 0 |
| Visit 7 Day 21 - Gamma Glutamyl Transferase (U/L) > 2 x ULN | 6 | 1 |
| Visit 10 Day 35 - Alanine Aminotransferase (U/L) > 3 x ULN | 0 | 1 |
| Visit 10 Day 35 - Alanine Aminotransferase (U/L) > 5 x ULN | 1 | 0 |
| Visit 10 Day 35 - Alkaline Phosphatase (U/L) > 1. 5 x ULN | 1 | 0 |
| Visit 10 Day 35 - Gamma Glutamyl Transferase (U/L) > 2 x ULN | 4 | 1 |
| Visit 10 or Early Termination Alanine Aminotransferase (U/L) >3x ULN | 0 | 1 |
| Visit 10 or Early Termination - Alanine Aminotransferase (U/L) >5x ULN | 1 | 0 |
| Visit 10 or Early Termination - Alkaline Phosphatase (U/L) > 1. 5 x ULN | 1 | 1 |
| Visit 10 or Early Termination - Bilirubin (umol/L) > 2 x ULN | 1 | 0 |
| Visit 10 or Early Termination - Gamma Glutamyl Transferase (U/L) > 2 x ULN | 7 | 1 |
| Visit 11 Day 42 - Bilirubin (umol/L) > 1. 5 x ULN | 1 | 0 |
| Visit 11 Day 42 - Gamma Glutamyl Transferase (U/L) > 2 x ULN | 3 | 0 |
Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 20 months). SAEs and Other AEs were assessed from first dose up to Day 42.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| KarXT | 0/125 (0%) | 1/125 (0.8%) | 69/125 (55.2%) |
| Placebo | 0/131 (0%) | 0/128 (0%) | 36/128 (28.1%) |
| Event | KarXT | Placebo |
|---|---|---|
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/125 | 0/128 |
| Event | KarXT | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 24/125 | 2/128 |
| DyspepsiaGastrointestinal disorders | 20/125 | 2/128 |
| VomitingGastrointestinal disorders | 20/125 | 1/128 |
| ConstipationGastrointestinal disorders | 16/125 | 5/128 |
| HeadacheNervous system disorders | 14/125 | 15/128 |
| InsomniaPsychiatric disorders | 7/125 | 10/128 |
| HypertensionVascular disorders | 8/125 | 2/128 |
| AnxietyPsychiatric disorders | 2/125 | 8/128 |
| DiarrhoeaGastrointestinal disorders | 7/125 | 1/128 |
| Age, Continuous(Years) | KarXT | Placebo | Total |
|---|---|---|---|
| Mean | 43.6 ± 11.44 | 42.6 ± 12.19 | 43.1 ± 11.82 |
| Sex: Female, Male(Participants) | KarXT | Placebo | Total |
|---|---|---|---|
| Female | 38 | 27 | 65 |
| Male | 87 | 104 | 191 |
| Ethnicity (NIH/OMB)(Participants) | KarXT | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 14 | 32 |
| Not Hispanic or Latino | 107 | 117 | 224 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | KarXT | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 79 | 77 | 156 |
| White | 45 | 53 | 98 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Nov 2022, 19 months.
Results were first posted in Dec 2024, 2 years after primary completion. A results delay was requested in Oct 2023.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 19 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium chloride